Eatontown, NJ (February 6, 2018) – West-Ward Pharmaceuticals, a wholly owned subsidiary of Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), announces the appointment of Daniel Motto as Executive Vice President of the US Injectables Division, where he will have responsibility for Sales, Marketing, Commercial Operations and Business Development. In this role, he will focus on maximizing West Ward/Hikma’s Injectables R&D portfolio, building new customer relationships and expanding business development.
“Daniel’s extensive industry knowledge, his hands-on, no-nonsense approach, and his experience in driving growth will be a real asset to our US business at this critical juncture,” said Riad Mechlaoui, CEO of the Injectables Division. “The dynamics of our industry are changing fast, and we are looking forward to the leadership, new ideas and experience Daniel will bring to the team.”
Mr. Motto joins Hikma from Teva where he most recently led its Global Business Development, Portfolio Management, Business Intelligence and Biosimilars businesses. Prior to that, he served as a member of the generics leadership team that drove organic growth, formed extensive partnerships and executed multiple acquisitions, including the acquisition of Actavis and Allergan that took Watson Labs from a smaller US generic player to a top 10 global pharmaceutical company. He has also held senior roles at Sandoz and Johnson & Johnson.
“I’m really pleased to be joining the Hikma team at such an important time in the company’s evolution. There is a great foundation to build upon and a solid team in place. I am looking forward to helping accelerate the growth of the US Injectables division and bring more new and important products to our customers and the patients they serve,” said Mr. Motto.
# # #
Keri Butler, West-Ward Pharmaceuticals
West-Ward is a wholly owned division of Hikma Pharmaceuticals PLC, a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.